{
    "root": "3140053a-3d5f-f403-e063-6394a90a6d37",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lacosamide",
    "value": "20250326",
    "ingredients": [
        {
            "name": "ACESULFAME POTASSIUM",
            "code": "23OV73Q5G9"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED",
            "code": "K679OBS311"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "NONCRYSTALLIZING SORBITOL SOLUTION",
            "code": "9E0S3UM200"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "ACESULFAME",
            "code": "MA3UYZ6K1H"
        },
        {
            "name": "AMMONIUM GLYCYRRHIZATE",
            "code": "3VRD35U26C"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1"
        },
        {
            "name": "LACOSAMIDE",
            "code": "563KS2PQY5"
        }
    ],
    "indications": "Lacosamide oral solution is indicated for: Treatment of partial-onset seizures in patients 4 years of age and older (1.1) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older (1.2)",
    "contraindications": "Adults (17 years and older): Initial dosage for monotherapy for the treatment of partial-onset seizures is 100 mg twice daily (2.1) Initial dosage for adjunctive therapy for the treatment of partial-onset seizures or primary generalized tonic-clonic seizures is 50 mg twice daily (2.1) Maximum recommended dosage for monotherapy and adjunctive therapy is 200 mg twice daily (2.1) Pediatric Patients 4 years to less than 17 years : The recommended dosage is based on body weight and is administered orally twice daily (2.1) Increase dosage based on clinical response and tolerability, no more frequently than once per week (2.1) Dose adjustment is recommended for severe renal impairment (2.4 , 12.3) Dose adjustment is recommended for mild or moderate hepatic impairment; use in patients with severe hepatic impairment is not recommended (2.5 , 12.3)",
    "warningsAndPrecautions": null,
    "adverseReactions": "None."
}